{"data":[{"accessionNo":"0000019617-26-000349","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock ($0.0001 par value)","eventDate":"2026-09-30","reportingPerson":"JPMORGAN CHASE & CO.","reportingCik":null,"personType":"HC","sharesOwned":4573701,"percentOfClass":5.5,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001172661-26-003428","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":7844311,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001172661-26-003428","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BALYASNY ASSET MANAGEMENT L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":7844311,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001172661-26-003428","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7844311,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001172661-26-003428","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7844311,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001172661-26-003428","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":7844311,"percentOfClass":9.99,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-097207","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":4175382,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-097207","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":4175382,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-097207","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":4175382,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-097207","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3662102,"percentOfClass":4.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000947871-26-000801","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"OrbiMed Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":3203050,"percentOfClass":4.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000947871-26-000801","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"OrbiMed Capital LLC","reportingCik":null,"personType":"IA","sharesOwned":744800,"percentOfClass":1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001011438-26-000515","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":6674913,"percentOfClass":8.4,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001011438-26-000515","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-06-30","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":6674913,"percentOfClass":8.4,"filedAt":"2026-08-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000093751-26-000489","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"LEXEO THERAPEUTICS INC","ticker":"LXEO","cusip":"52886X107","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":4354775,"percentOfClass":5.5,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-225157","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7176144,"percentOfClass":9.69,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-225157","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7176144,"percentOfClass":9.69,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-225157","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":7176144,"percentOfClass":9.69,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-225157","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Balyasny Asset Management L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":7176144,"percentOfClass":9.69,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-225157","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":7176144,"percentOfClass":9.69,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-062613","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":6184134,"percentOfClass":8.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-062613","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":6184134,"percentOfClass":8.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-062613","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":6184134,"percentOfClass":8.3,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-062613","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":5449272,"percentOfClass":7.4,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000919574-26-002223","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common stock, par value $0.0001","eventDate":"2026-04-06","reportingPerson":"AARON COWEN","reportingCik":null,"personType":"HC,IN","sharesOwned":5674778,"percentOfClass":7.7,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000919574-26-002223","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common stock, par value $0.0001","eventDate":"2026-04-06","reportingPerson":"SUVRETTA CAPITAL MANAGEMENT, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":5674778,"percentOfClass":7.7,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000919574-26-002223","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":"52886X107","securityClass":"Common stock, par value $0.0001","eventDate":"2026-04-06","reportingPerson":"Averill Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":4827730,"percentOfClass":6.5,"filedAt":"2026-04-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000102909-26-001619","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics Inc","ticker":"LXEO","cusip":"52886X107","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-052896","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Balyasny Asset Management L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":7221555,"percentOfClass":9.89,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-052896","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":7221555,"percentOfClass":9.89,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-052896","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7221555,"percentOfClass":9.89,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-052896","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":7221555,"percentOfClass":9.89,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-26-052896","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":7221555,"percentOfClass":9.89,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016498","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value) (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Kenneth Griffin","reportingCik":null,"personType":"HC,IN","sharesOwned":5498219,"percentOfClass":7.4,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016498","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value) (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Citadel Advisors Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":5405269,"percentOfClass":7.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016498","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value) (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Citadel Advisors LLC","reportingCik":null,"personType":"IA,HC,OO","sharesOwned":5405269,"percentOfClass":7.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016498","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value) (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Citadel GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":5405269,"percentOfClass":7.2,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016355","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":4763198,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016355","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":4763198,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016355","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":4763198,"percentOfClass":6.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016355","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":4207159,"percentOfClass":5.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016498","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value) (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Citadel Securities GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":92950,"percentOfClass":0.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016498","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value) (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Citadel Securities Group LP","reportingCik":null,"personType":"HC,PN","sharesOwned":92950,"percentOfClass":0.1,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-26-016498","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value) (the \"Shares\")","eventDate":"2025-12-31","reportingPerson":"Citadel Securities LLC","reportingCik":null,"personType":"BD,OO","sharesOwned":6600,"percentOfClass":0,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":3698271,"percentOfClass":5.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences Public Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3698271,"percentOfClass":5.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLSP, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3698271,"percentOfClass":5.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":406246,"percentOfClass":0.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":406246,"percentOfClass":0.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XII, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":406246,"percentOfClass":0.6,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":232784,"percentOfClass":0.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences XI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":232784,"percentOfClass":0.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS XI, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":232784,"percentOfClass":0.3,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"James N. Topper","reportingCik":null,"personType":"IN","sharesOwned":87424,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Frazier Life Sciences X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":87424,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.P.","reportingCik":null,"personType":"PN","sharesOwned":87424,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"FHMLS X, L.L.C.","reportingCik":null,"personType":"OO","sharesOwned":87424,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001231919-26-000153","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Patrick J. Heron","reportingCik":null,"personType":"IN","sharesOwned":87424,"percentOfClass":0.1,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000102909-26-000183","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics Inc","ticker":"LXEO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":3894310,"percentOfClass":5.33,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001315863-26-000099","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-01-22","reportingPerson":"Michael Cho","reportingCik":null,"personType":"IN,HC","sharesOwned":5217660,"percentOfClass":7.1,"filedAt":"2026-01-29","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001315863-26-000099","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-01-22","reportingPerson":"Affinity Asset Advisors, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":5217660,"percentOfClass":7.1,"filedAt":"2026-01-29","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0002012383-26-000688","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":4885814,"percentOfClass":6.7,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001274173-25-000338","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001907108","issuerName":"LEXEO THERAPEUTICS, INC.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-11-28","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"IA,HC","sharesOwned":7291434,"percentOfClass":9.99,"filedAt":"2025-12-08","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-114635","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-13","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":3671999,"percentOfClass":5,"filedAt":"2025-11-20","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-114635","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-13","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":3671999,"percentOfClass":5,"filedAt":"2025-11-20","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-114635","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-13","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":3671999,"percentOfClass":5,"filedAt":"2025-11-20","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-114635","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-13","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3244093,"percentOfClass":4.4,"filedAt":"2025-11-20","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001274173-25-000315","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001907108","issuerName":"LEXEO THERAPEUTICS, INC.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"IA,HC","sharesOwned":6105527,"percentOfClass":11.3,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-281249","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Dmitry Balyasny","reportingCik":null,"personType":"HC,IN","sharesOwned":5394721,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-281249","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Dames GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":5394721,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-281249","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Balyasny Asset Management Holdings LP","reportingCik":null,"personType":"HC,PN","sharesOwned":5394721,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-281249","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"BAM GP LLC","reportingCik":null,"personType":"HC,OO","sharesOwned":5394721,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-281249","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Balyasny Asset Management L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":5394721,"percentOfClass":9.99,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001274173-25-000315","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001907108","issuerName":"LEXEO THERAPEUTICS, INC.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"Janus Henderson Biotech Innovation Master Fund Ltd","reportingCik":null,"personType":"IV","sharesOwned":4076465,"percentOfClass":7.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000902664-25-004978","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Ryan Wilder","reportingCik":null,"personType":"HC,IN","sharesOwned":4117302,"percentOfClass":7.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0000902664-25-004978","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Vestal Point Capital, LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4117302,"percentOfClass":7.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-283019","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value)","eventDate":"2025-09-30","reportingPerson":"Longitude Capital Partners IV, LLC","reportingCik":null,"personType":"OO","sharesOwned":2765381,"percentOfClass":3.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-283019","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value)","eventDate":"2025-09-30","reportingPerson":"Juliet Tammenoms Bakker","reportingCik":null,"personType":"IN","sharesOwned":2765381,"percentOfClass":3.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-283019","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value)","eventDate":"2025-09-30","reportingPerson":"Patrick G. Enright","reportingCik":null,"personType":"IN","sharesOwned":2765381,"percentOfClass":3.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001193125-25-283019","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock ($0.0001 par value)","eventDate":"2025-09-30","reportingPerson":"Longitude Venture Partners IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2765381,"percentOfClass":3.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-108535","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":2313642,"percentOfClass":3.2,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-108535","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":2313642,"percentOfClass":3.2,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-108535","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":2313642,"percentOfClass":3.2,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001104659-25-108535","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Integrated Core Strategies (US) LLC","reportingCik":null,"personType":"OO","sharesOwned":2065700,"percentOfClass":2.8,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001346824-25-000027","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-20","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5000000,"percentOfClass":6.9,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001346824-25-000027","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-20","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":5000000,"percentOfClass":6.9,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001346824-25-000027","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-20","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":5000000,"percentOfClass":6.9,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0001346824-25-000027","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-10-20","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":5000000,"percentOfClass":6.9,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"},{"accessionNo":"0002012383-25-002600","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001907108","issuerName":"Lexeo Therapeutics, Inc.","ticker":"LXEO","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":2168444,"percentOfClass":4,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo"}],"updatedAt":"2026-10-23T20:19:06.900Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/lxeo","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}